Ryan Peter Englander

Dr. Ryan Peter Englander

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HEHakimeh Ebrahimi-Nik
Hakimeh Ebrahimi-Nik
MMMarmar Moussa
Marmar Moussa
RERyan Peter Englander
Ryan Peter Englander
SSSummit Singhaviranon
Summit Singhaviranon
JMJustine Michaux
Justine Michaux
PSPramod K. Srivastava
Pramod K. Srivastava
High-affinity MHC I-peptide interactions are considered essential for immunogenicity. However, some neo-epitopes with low affinity for MHC I have been reported to elicit CD8 T cell dependent tumor rejection in immunization-challenge studies. Here we show in a mouse model that a neo-epitope that poorly binds to MHC I is able to enhance the immunogenicity of a tumor in the absence of immunization. Fibrosarcoma cells with a naturally occurring mutation are edited to their wild type counterpart; the mutation is then re-introduced in order to obtain a cell line that is genetically identical to the wild type except for the neo-epitope-encoding mutation. Upon transplantation into syngeneic mice, all three cell lines form tumors that are infiltrated with activated T cells. However, lymphocytes from the two tumors that harbor the mutation show significantly stronger transcriptional signatures of cytotoxicity and TCR engagement, and induce greater breadth of TCR reactivity than those of the wild type tumors. Structural modeling of the neo-epitope peptide/MHC I pairs suggests increased hydrophobicity of the neo-epitope surface, consistent with higher TCR reactivity. These results confirm the in vivo immunogenicity of low affinity or ‘non-binding’ epitopes that do not follow the canonical concept of MHC I-peptide recognition.

1 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CBCory A. Brennick
Cory A. Brennick
MGMariam M. George
Mariam M. George
MMMarmar M. Moussa
Marmar M. Moussa
AHAdam T. Hagymasi
Adam T. Hagymasi
SSSahar Al Seesi
Sahar Al Seesi
PSPramod K. Srivastava
Pramod K. Srivastava
Identification of neoepitopes that are effective in cancer therapy is a major challenge in creating cancer vaccines. Here, using an entirely unbiased approach, we queried all possible neoepitopes in a mouse cancer model and asked which of those are effective in mediating tumor rejection and, independently, in eliciting a measurable CD8 response. This analysis uncovered a large trove of effective anticancer neoepitopes that have strikingly different properties from conventional epitopes and suggested an algorithm to predict them. It also revealed that our current methods of prediction discard the overwhelming majority of true anticancer neoepitopes. These results from a single mouse model were validated in another antigenically distinct mouse cancer model and are consistent with data reported in human studies. Structural modeling showed how the MHC I–presented neoepitopes had an altered conformation, higher stability, or increased exposure to T cell receptors as compared with the unmutated counterparts. T cells elicited by the active neoepitopes identified here demonstrated a stem-like early dysfunctional phenotype associated with effective responses against viruses and tumors of transgenic mice. These abundant anticancer neoepitopes, which have not been tested in human studies thus far, can be exploited for generation of personalized human cancer vaccines.

19 August 2025 in bioRxiv
Verified
Preprint
Open access
RERyan Peter Englander
Ryan Peter Englander
MBMattia Brugiolo
Mattia Brugiolo
TWTe-Chia Wu
Te-Chia Wu
MKMitch Kostich
Mitch Kostich
NLNathan K Leclair
Nathan K Leclair
OAOlga Anczukow
Olga Anczukow
Immunotherapy benefits only a subset of lung cancer patients, and the molecular determinants of variable outcomes remain unclear. Using long-read RNA-sequencing we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified over 180,000 full-length mRNA isoforms, more than half of which were novel and many of which occurred in immune-related genes, particularly within the type I interferon response pathway. We discovered retained introns in the STAT2 gene that produce altered protein isoforms that regulate immune signaling and interferon responses. Furthermore, STAT2 intron retention levels predicted patient responses to checkpoint inhibitors. These findings position alternative splicing as a key regulator of tumor immune responses and reveal mRNA splicing alterations as potential biomarkers to identify patients who might respond to cancer immunotherapy.

22 October 2026 in Science
Verified
Journal Article
Closed access
RERyan Peter Englander
Ryan Peter Englander
MBMattia Brugiolo
Mattia Brugiolo
MDMaëva Devoucoux
Maëva Devoucoux
TWTe-Chia Wu
Te-Chia Wu
MKMitch Kostich
Mitch Kostich
OAOlga Anczukow
Olga Anczukow
Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and enabled considerable therapeutic advances for treating various diseases, including lung cancer. However, the molecular determinants of variable patient outcomes remain unclear. Using long-read RNA sequencing, we mapped the landscape of alternative RNA splicing in human primary lung adenocarcinomas. We identified more than 149,000 full-length messenger RNA (mRNA) isoforms, more than half of which were unannotated and many that occurred in immune-related genes, particularly within the type I interferon response pathway. We functionally characterized retained introns in the STAT2 gene that produced altered protein isoforms that regulated immune signaling and interferon responses and correlated with patient survival after anti–programmed death-ligand 1 (PD-L1) immunotherapy. These findings position alternative splicing as a regulator of tumor immune responses and reveal intron retention in STAT2 as an interferon regulatory axis that correlates with PD-L1 checkpoint inhibitor response.

21 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NLNathan K. Leclair
Nathan K. Leclair
MBMattia Brugiolo
Mattia Brugiolo
IWIsha Walawalkar
Isha Walawalkar
MYMarina Yurieva
Marina Yurieva
HKHyeon Gu Kang
Hyeon Gu Kang
OAOlga Anczukow
Olga Anczukow
SR proteins are essential splicing regulators whose expression is controlled in part through poison exons (PEs) -- ultraconserved non-coding exons that trigger nonsense-mediated decay -- yet the biological functions of these elements remain undefined. Here, we show that homozygous deletion of SRSF3-PE or TRA2B-PE is selected against in mouse embryos and human induced pluripotent stem cells (iPSCs), and that conditional PE deletion causes apoptotic death in iPSCs but is tolerated in post-mitotic neurons, revealing a proliferative-state-specific requirement. Mechanistically, PE deletion elevates SR protein levels, triggers widespread splicing dysregulation, and disrupts the correct splicing of a mitotic gene network associated with spindle defects and mitotic errors. These findings establish ultraconserved poison exons as essential regulators of mitotic splicing fidelity and stem cell viability.

6 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VPVaishvik Patel
Vaishvik Patel
AAAhmed Al-Ghazawy
Ahmed Al-Ghazawy
JPJay Patel
Jay Patel
OAOluwakorede Akele
Oluwakorede Akele
RERyan Peter Englander
Ryan Peter Englander
KDKhagendra Dahal
Khagendra Dahal
Background/Objectives: Patients with prior coronary artery bypass grafting (CABG) frequently require repeat percutaneous coronary intervention (PCI), but the optimal target—native coronary artery or saphenous vein graft (SVG)—remains uncertain. We performed an updated systematic review and random-effects meta-analysis comparing clinical and procedural outcomes of native coronary artery PCI versus SVG PCI. Methods: PubMed, Embase, and the Cochrane Library (Cochrane Central Register of Controlled Trials) were searched from inception through May 2026. Results: Twenty-five studies (343,524 patients) were included, with 21 contributing to the MACE and/or all-cause mortality analyses. Compared with native-vessel PCI, SVG PCI was associated with higher rates of major adverse cardiovascular events (MACE) (risk ratio [RR] 1.30, 95% confidence interval [CI] 1.05–1.60; p = 0.017), all-cause mortality (RR 1.47, 95% CI 1.19–1.81; p < 0.001), myocardial infarction (RR 1.64, 95% CI 1.31–2.05; p < 0.001), in-stent restenosis (RR 1.71, 95% CI 1.19–2.44; p = 0.004), and target lesion revascularization (RR 1.70, 95% CI 1.16–2.47; p = 0.006). After exclusion of the single randomized trial, associations for MACE (RR 1.38, 95% CI 1.12–1.71) and all-cause mortality (RR 1.50, 95% CI 1.21–1.85) were slightly stronger. Cardiac death, stroke, and bleeding did not differ significantly. Findings for MACE and target lesion revascularization were sensitive to the omission of single studies. In the exploratory drug-eluting stent-predominant subgroup, effect directions were generally consistent. Despite these associations, most included studies were observational, and substantial heterogeneity and residual confounding remain important limitations (95% prediction intervals for MACE and mortality included the null), and the certainty of evidence (GRADE) was low to very low. Conclusions: SVG PCI was associated with less favorable long-term outcomes than native coronary artery PCI, although these findings do not establish causality and should be interpreted alongside randomized evidence supporting individualized, anatomy-based target selection. Adequately powered randomized trials with extended follow-up are needed to define the optimal revascularization strategy across the spectrum of post-CABG anatomy.